ADL 100116

Drug Profile

ADL 100116

Alternative Names: ADL 0100016; ADL 10-0116

Latest Information Update: 10 Jul 2006

Price : $50

At a glance

  • Originator Adolor Corporation
  • Class Analgesics
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 10 Jul 2006 No development reported - Phase-I for Pain in USA (PO)
  • 14 Sep 2001 Phase-I clinical trials for Pain in USA (PO)
  • 27 Jul 2001 Preclinical development for Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top